10-QPeriod: Q2 FY2012

INTUITIVE SURGICAL INC Quarterly Report for Q2 Ended Jun 30, 2012

Filed July 23, 2012For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) reported strong financial results for the quarter and six months ended June 30, 2012. Total revenue increased by 26% year-over-year for the quarter, reaching $536.5 million, driven by robust growth in both product and service revenues. The company's installed base of da Vinci Surgical Systems grew to 2,341 units, reflecting continued adoption of its advanced surgical technology. Profitability also showed significant improvement, with operating income up 34% and net income rising to $154.9 million for the quarter. The company continues to invest in research and development and expand its commercial operations, evidenced by an increase in headcount and R&D expenses. ISRG maintains a strong liquidity position with $2.6 billion in cash, cash equivalents, and investments as of June 30, 2012, indicating a healthy financial foundation for future growth.

Financial Highlights

45 data points
Beta

Revenue

$536.50M

72.0% Gross Margin

Net Income

$154.90M

28.9% Net Margin

EPS (Diluted)

$0.42

Total Assets

$3.63B

Cash & Equivalents

$484.40M

Free Cash Flow

$210.80M

Financial Statements
Beta
Revenue$536.50M
Cost of Revenue$150.10M
Gross Profit$386.40M
R&D Expenses$40.20M
SG&A Expenses$120.90M
Operating Expenses$161.10M
Operating Income$225.30M
Net Income$154.90M
EPS (Basic)$0.43
EPS (Diluted)$0.42
Shares Outstanding (Basic)359.10M
Shares Outstanding (Diluted)371.70M

Key Highlights

  • 1Total revenue increased 26% to $536.5 million for the three months ended June 30, 2012, compared to $425.7 million in the prior year period.
  • 2da Vinci procedures performed increased by approximately 26% year-over-year, indicating strong demand and utilization.
  • 3Instruments and accessories revenue grew 30% to $223.7 million, demonstrating the recurring revenue strength of the business model.
  • 4Recurring revenue represented 57% of total revenue, up from 56% in the prior year, highlighting the increasing contribution from services and consumables.
  • 5The company sold 150 da Vinci Surgical Systems in the quarter, a 16% increase from 129 units in the same period last year.
  • 6Operating income increased by 34% to $225.3 million, showcasing improved operational efficiency and leverage.
  • 7The installed base of da Vinci Surgical Systems reached 2,341 units as of June 30, 2012, a significant expansion from prior periods.

Frequently Asked Questions

Revenue growth was primarily driven by the continued adoption of da Vinci Surgery, with strong performance in U.S. gynecologic procedures (dVH, sacrocolpopexy, endometriosis resection, myomectomy) and U.S. general surgery (cholecystectomy, colon procedures). Growth in da Vinci Prostatectomy (dVP) in international markets also contributed, though dVP in the U.S. saw a decline. An increase in system unit sales and average selling prices, along with robust instrument and accessory sales tied to higher procedure volumes, were key factors.

Intuitive Surgical demonstrated strong operating leverage, with operating income increasing by 34% to $225.3 million. While selling, general, and administrative expenses and R&D expenses increased to support business expansion, revenue growth outpaced these increases. The company also benefits from a high gross margin, particularly on product revenue (72.9%), and improving margins on service revenue (67.4%).

Recurring revenue, comprising instruments, accessories, and services, continues to be a significant and growing portion of total revenue, reaching 57% in Q2 2012. The company expects this trend to continue, driven by an expanding installed base of da Vinci systems, increasing procedure volumes, and customer loyalty to service contracts. This recurring revenue stream provides a stable and predictable revenue base.

The company is involved in certain legal proceedings, including a past class action lawsuit that was dismissed with prejudice in favor of the company, and shareholder derivative lawsuits. While the company believes it has meritorious defenses and the resolution is unlikely to have a material adverse effect, it cannot provide assurance of the outcome. No amounts have been accrued as the outcome is uncertain. Other than these, there are no other material new legal or regulatory issues mentioned in this report.